ATE520653T1 - Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen - Google Patents
Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhenInfo
- Publication number
- ATE520653T1 ATE520653T1 AT03757173T AT03757173T ATE520653T1 AT E520653 T1 ATE520653 T1 AT E520653T1 AT 03757173 T AT03757173 T AT 03757173T AT 03757173 T AT03757173 T AT 03757173T AT E520653 T1 ATE520653 T1 AT E520653T1
- Authority
- AT
- Austria
- Prior art keywords
- dna damage
- cell cycle
- compounds
- treatments
- stop
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000012820 cell cycle checkpoint Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000012623 DNA damaging agent Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000001235 sensitizing effect Effects 0.000 abstract 1
- 230000016596 traversing start control point of mitotic cell cycle Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/36—Esters of dithiocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38693002P | 2002-06-06 | 2002-06-06 | |
| PCT/IB2003/003164 WO2003104181A2 (en) | 2002-06-06 | 2003-06-06 | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE520653T1 true ATE520653T1 (de) | 2011-09-15 |
Family
ID=29736236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03757173T ATE520653T1 (de) | 2002-06-06 | 2003-06-06 | Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7030111B2 (de) |
| EP (1) | EP1511713B8 (de) |
| JP (2) | JP4919598B2 (de) |
| KR (1) | KR100984951B1 (de) |
| CN (1) | CN100577631C (de) |
| AT (1) | ATE520653T1 (de) |
| AU (1) | AU2003247044B8 (de) |
| CA (1) | CA2487388C (de) |
| ES (1) | ES2369534T3 (de) |
| IL (2) | IL165323A0 (de) |
| NO (1) | NO20045556L (de) |
| WO (1) | WO2003104181A2 (de) |
| ZA (1) | ZA200409650B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL165323A0 (en) * | 2002-06-06 | 2006-01-15 | Canbas Co Ltd | Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| EP1664340A1 (de) * | 2003-08-08 | 2006-06-07 | Canbas Co., Ltd. | Empfindlichkeitstest zur vorhersage der wirksamkeit von antikrebstherapien |
| JPWO2007097010A1 (ja) * | 2006-02-21 | 2009-07-09 | 学校法人北里研究所 | Ｆｋｉ−２３４２物質およびその製造法 |
| EP2081565A2 (de) * | 2006-10-13 | 2009-07-29 | Reliance Life Sciences Pvt., Ltd. | Zimtsäure-, vanillinsäure- und benzofuranderivate zur verwendung bei der behandlung von entzündungen und krebs |
| EP4074704A1 (de) * | 2007-04-11 | 2022-10-19 | CanBas Co., Ltd. | Chinolin-verbindungen mit krebshemmender wirkung |
| EP3578974A1 (de) * | 2018-06-08 | 2019-12-11 | Novagray | Bleomycin zur nachahmung der wirkung ionisierender strahlung auf t-zellen |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2913483A (en) * | 1958-05-08 | 1959-11-17 | Dow Chemical Co | Lower alkylphenyl 2, 4-dichloro-benzoates |
| DE2049865A1 (en) * | 1970-10-10 | 1972-04-13 | Dynamit Nobel Ag, 5210 Troisdorf | Aromatic acid aryl esters - prepd from aromatic trichloromethyl cpds phenols and water |
| US4394389A (en) * | 1979-03-01 | 1983-07-19 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors |
| JPS56110777A (en) * | 1980-02-07 | 1981-09-02 | Chisso Corp | Ester derivative of 4-fluorobenzoic acid |
| US4612386A (en) * | 1980-09-16 | 1986-09-16 | The Dow Chemical Company | Process for making esters |
| JPS58188838A (ja) * | 1982-04-27 | 1983-11-04 | Chisso Corp | ４−（４′−フルオロベンゾイルオキシ）フエノ−ルのエステル誘導体 |
| US4934389A (en) * | 1988-12-06 | 1990-06-19 | Pettiford William L | Dental floss dispenser |
| FR2649977B1 (fr) * | 1989-07-18 | 1991-10-04 | Cird | Esters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| JP2696434B2 (ja) * | 1991-01-23 | 1998-01-14 | 富士写真フイルム株式会社 | 画像形成方法 |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| CA2216559A1 (en) | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
| DE69911935T3 (de) | 1998-03-13 | 2008-02-07 | The University Of British Columbia, Vancouver | Granulatimide-derivate zur behandlung von krebs |
| IL138572A0 (en) | 1998-03-25 | 2001-10-31 | Biosource Genetics Corp | Benzoate derivatives and pharmaceutical compositions containing the same |
| DE60019318T2 (de) | 1999-09-22 | 2006-03-09 | Canbas Co., Ltd., Numazu | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe |
| US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| KR101103412B1 (ko) * | 2002-01-17 | 2012-01-06 | 다케다 파머수티컬 컴패니 리미티드 | 항증식 활성을 지니고／지니거나 핵산 손상제 또는처리제를 증강시키는 펩티드 및 펩티드모방체 |
| AU2003243318A1 (en) * | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| IL165323A0 (en) * | 2002-06-06 | 2006-01-15 | Canbas Co Ltd | Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| US6881573B2 (en) * | 2003-09-12 | 2005-04-19 | Allan L. Louderback | Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses |
-
2003
- 2003-06-06 IL IL16532303A patent/IL165323A0/xx unknown
- 2003-06-06 US US10/457,029 patent/US7030111B2/en not_active Expired - Fee Related
- 2003-06-06 JP JP2004511251A patent/JP4919598B2/ja not_active Expired - Fee Related
- 2003-06-06 ES ES03757173T patent/ES2369534T3/es not_active Expired - Lifetime
- 2003-06-06 WO PCT/IB2003/003164 patent/WO2003104181A2/en not_active Ceased
- 2003-06-06 CN CN03818476A patent/CN100577631C/zh not_active Expired - Fee Related
- 2003-06-06 AT AT03757173T patent/ATE520653T1/de not_active IP Right Cessation
- 2003-06-06 AU AU2003247044A patent/AU2003247044B8/en not_active Ceased
- 2003-06-06 CA CA2487388A patent/CA2487388C/en not_active Expired - Fee Related
- 2003-06-06 KR KR1020047019826A patent/KR100984951B1/ko not_active Expired - Fee Related
- 2003-06-06 EP EP03757173A patent/EP1511713B8/de not_active Expired - Lifetime
-
2004
- 2004-11-22 IL IL165323A patent/IL165323A/en not_active IP Right Cessation
- 2004-11-29 ZA ZA200409650A patent/ZA200409650B/en unknown
- 2004-12-20 NO NO20045556A patent/NO20045556L/no unknown
-
2006
- 2006-01-17 US US11/334,160 patent/US7407985B2/en not_active Expired - Lifetime
-
2008
- 2008-06-02 US US12/131,639 patent/US7629364B2/en not_active Expired - Fee Related
- 2008-06-02 US US12/131,564 patent/US7652042B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 JP JP2010099281A patent/JP2010168398A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003247044B2 (en) | 2009-03-26 |
| IL165323A0 (en) | 2006-01-15 |
| KR20050019730A (ko) | 2005-03-03 |
| JP2005528457A (ja) | 2005-09-22 |
| AU2003247044B8 (en) | 2009-04-09 |
| US7030111B2 (en) | 2006-04-18 |
| CN1671644A (zh) | 2005-09-21 |
| EP1511713B8 (de) | 2012-02-08 |
| US20080227827A1 (en) | 2008-09-18 |
| US7407985B2 (en) | 2008-08-05 |
| US20040198727A1 (en) | 2004-10-07 |
| US20060122269A1 (en) | 2006-06-08 |
| WO2003104181A2 (en) | 2003-12-18 |
| US7652042B2 (en) | 2010-01-26 |
| WO2003104181A3 (en) | 2004-07-29 |
| NO20045556L (no) | 2005-03-04 |
| CN100577631C (zh) | 2010-01-06 |
| ZA200409650B (en) | 2006-09-27 |
| CA2487388A1 (en) | 2003-12-18 |
| AU2003247044A1 (en) | 2003-12-22 |
| CA2487388C (en) | 2011-05-10 |
| EP1511713A2 (de) | 2005-03-09 |
| EP1511713B1 (de) | 2011-08-17 |
| KR100984951B1 (ko) | 2010-10-01 |
| US7629364B2 (en) | 2009-12-08 |
| JP4919598B2 (ja) | 2012-04-18 |
| ES2369534T3 (es) | 2011-12-01 |
| US20080293137A1 (en) | 2008-11-27 |
| JP2010168398A (ja) | 2010-08-05 |
| IL165323A (en) | 2015-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE415397T1 (de) | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| MX374896B (es) | Compuestos con actividad anticáncer. | |
| DE602004025803D1 (de) | Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen | |
| ATE423087T1 (de) | Proteasome inhibitoren und deren verwendung | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| NO20033858L (no) | Aryl- og heteroarylurea-CHK1-inhibitorer for anvendelse som radiosensitiviseringsmidler og chamosensitiviseringsmidler | |
| DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
| NO20081434L (no) | 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser | |
| PT1660507E (pt) | Inibidores de proteassoma e seus métodos de utilização | |
| ATE325125T1 (de) | Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden | |
| ATE478671T1 (de) | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität | |
| MX2007011545A (es) | Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr. | |
| ATE547107T1 (de) | Verwendung von selenhefe in der behandlung von alzheimers krankheit | |
| DE60019318D1 (de) | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe | |
| ATE413392T1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| ATE520653T1 (de) | Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen | |
| DE60135482D1 (de) | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen | |
| NO20054361L (no) | Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte | |
| EA200800374A1 (ru) | 1,4-дигидропиридин-конденсированные гетероциклы, способы их получения, применение и содержащие их композиции | |
| DE60328772D1 (de) | Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen | |
| DE602006012115D1 (de) | Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga | |
| ATE410415T1 (de) | Neue verbindungen | |
| EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |